|
Novartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to work
|
05 December 2016 |
|
Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)
|
21 November 2016 |
|
Novartis announces AMG 334 significantly reduces monthly migraine days in second pivotal Phase III episodic migraine study
|
16 November 2016 |
|
Novartis wins two prestigious Prix Galien Foundation Awards
|
31 October 2016 |
|
Novartis delivered solid third quarter
|
25 October 2016 |
|
Novartis reports over half of psoriasis patients do not reach the achievable treatment goal of clear skin in largest global survey
|
04 October 2016 |
|
Sandoz invites young entrepreneurs to enter #SandozHACk, a global competition to help solve healthcare access challenges
|
28 September 2016 |
|
Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs
|
22 September 2016 |
|
Novartis Foundation showcases progress in leprosy elimination programs at 19th International Leprosy Congress
|
15 September 2016 |
|
Novartis convenes experts to discuss new technologies in healthcare at Novartis International BioCamp
|
29 August 2016 |